Literature DB >> 1694221

Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.

C Sibille1, P Chomez, C Wildmann, A Van Pel, E De Plaen, J L Maryanski, V de Bergeyck, T Boon.   

Abstract

Mutagen treatment of mouse tumor cell line P815 produces tum- variants that are rejected by syngeneic mice because they express new transplantation antigens. These tum- antigens are recognized by cytotoxic T lymphocytes (CTL) but induce no detectable antibody response. By transfecting P815 cell line P1.HTR with DNA of tum- variant P198, we obtained transfectants expressing tum- antigen P198 that could be identified on the basis of their ability to stimulate anti-P198 CTL. This was repeated with DNA of a cosmid library derived from variant P198, and a cosmid carrying the sequence encoding antigen P198 was recovered from a transfectant. Gene P198 is 3 kb long and contains eight exons. It shows no homology with previously identified tum- gene P91A, nor with any gene presently recorded in the data banks. The long open reading frame codes for a 23.5-kD protein. The antigenic allele of gene P198 differs from the normal allele by a point mutation located in exon 7. This mutation causes an Ala to Thr change, and was shown by site-directed mutagenesis to be responsible for the expression of the antigen. An 11-amino acid synthetic peptide covering the sequence surrounding the tum- mutation rendered P815 cells sensitive to lysis by anti-P198 CTL. The homologous peptide corresponding to the normal sequence of the gene did not, but it was able to compete for binding to major histocompatibility complex molecule Kd. We conclude that tum- mutation P198 generates a new epitope recognized by syngeneic T cells. As observed with gene P91A, we found that a fragment of gene P198 that contained only exons 3-7, cloned in nonexpression vectors, transferred efficiently the expression of the antigen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694221      PMCID: PMC2188179          DOI: 10.1084/jem.172.1.35

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  Genetic and physical linkage of exogenous sequences in transformed cells.

Authors:  M Perucho; D Hanahan; M Wigler
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

2.  Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors.

Authors:  P Frost; R S Kerbel; E Bauer; R Tartamella-Biondo; W Cefalu
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

Review 3.  Antigenic tumor cell variants obtained with mutagens.

Authors:  T Boon
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

4.  Double cos site vectors: simplified cosmid cloning.

Authors:  P F Bates; R A Swift
Journal:  Gene       Date:  1983-12       Impact factor: 3.688

5.  Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer.

Authors:  D H Margulies; G A Evans; K Ozato; R D Camerini-Otero; K Tanaka; E Appella; J G Seidman
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

6.  The construction of cosmid libraries which can be used to transform eukaryotic cells.

Authors:  F G Grosveld; T Lund; E J Murray; A L Mellor; H H Dahl; R A Flavell
Journal:  Nucleic Acids Res       Date:  1982-11-11       Impact factor: 16.971

7.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.

Authors:  J L Maryanski; J Van Snick; J C Cerottini; T Boon
Journal:  Eur J Immunol       Date:  1982-05       Impact factor: 5.532

8.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.

Authors:  J L Maryanski; M Marchand; C Uyttenhove; T Boon
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

9.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids.

Authors:  J L Maryanski; J Szpirer; C Szpirer; T Boon
Journal:  Somatic Cell Genet       Date:  1983-05

10.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  39 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  A new approach to the cloning of genes encoding T-cell epitopes.

Authors:  D M Scott; P J Dyson; E Simpson
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  Mapping of the genes encoding tum- transplantation antigens P91A, P35B, and P198.

Authors:  P J Dyson; C de Smet; A M Knight; D Simon-Chazottes; J L Guénet; T Boon
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

4.  Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Authors:  Mary Philip; Andrea Schietinger; Hans Schreiber
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

5.  Do we need a pepton hypothesis?

Authors:  K F Lindahl
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 6.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

Review 7.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

8.  Efficient expression of tum- antigen P91A by transfected subgenic fragments.

Authors:  P Chomez; E De Plaen; A Van Pel; C De Smet; J P Szikora; C Lurquin; A M Lebacq-Verheyden; T Boon
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 9.  Neoantigen-based cancer immunotherapy.

Authors:  Sara Bobisse; Periklis G Foukas; George Coukos; Alexandre Harari
Journal:  Ann Transl Med       Date:  2016-07

10.  Immunological characterization of tumor-rejection antigens on ultraviolet-light-induced tumors originating in the CB6F1 mouse.

Authors:  T Kitajima; M Iwashiro; K Kuribayashi; S Imamura
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.